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This BMJ Rapid Recommendation 
article is one of a series that 
provides clinicians with trustworthy 
recommendations for potentially 
practice changing evidence. 
BMJ Rapid Recommendations 
represent a collaborative effort 
between the MAGIC group (http://
magicproject.org/) and The 
BMJ. A summary is offered here 
and the full version including 
decision aids is on the MAGICapp 
(https://app.magicapp.org), for all 
devices in multilayered formats. 
Those reading and using these 
recommendations should consider 
individual patient circumstances, 
and their values and preferences 
and may want to use consultation 
decision aids in MAGICapp to 
facilitate shared decision making 
with patients. We encourage 
adaptation and contextualisation 
of our recommendations to local or 
other contexts. Those considering 
use or adaptation of content may 
go to MAGICapp to link or extract 
its content or contact The BMJ for 
permission to reuse content in this 
article.
ABSTRACT
Clinical question What are the benefits and harms of thyroid hormones for adults with subclinical hypothyroidism 
(SCH)? This guideline was triggered by a recent systematic review of randomised controlled trials, which could 
alter practice.
Current practice Current guidelines tend to recommend thyroid hormones for adults with thyroid stimulating 
hormone (TSH) levels >10 mIU/L and for people with lower TSH values who are young, symptomatic, or have 
specific indications for prescribing.
Recommendation The guideline panel issues a strong recommendation against thyroid hormones in adults with 
SCH (elevated TSH levels and normal free T4 (thyroxine) levels). It does not apply to women who are trying to 
become pregnant or patients with TSH >20 mIU/L. It may not apply to patients with severe symptoms or young 
adults (such as those ≤30 years old).
How this guideline was created A guideline panel including patients, clinicians, and methodologists produced 
this recommendation in adherence with standards for trustworthy guidelines using the GRADE approach.
The evidence The systematic review included 21 trials with 2192 participants. For adults with SCH, thyroid 
hormones consistently demonstrate no clinically relevant benefits for quality of life or thyroid related symptoms, 
including depressive symptoms, fatigue, and body mass index (moderate to high quality evidence). Thyroid 
hormones may have little or no effect on cardiovascular events or mortality (low quality evidence), but harms were 
measured in only one trial with few events at two years’ follow-up.
Understanding the recommendation The panel concluded that almost all adults with SCH would not benefit from 
treatment with thyroid hormones. Other factors in the strong recommendation include the burden of lifelong 
management and uncertainty on potential harms. Instead, clinicians should monitor the progression or resolution 
of the thyroid dysfunction in these adults. Recommendations are made actionable for clinicians and their patients 
through visual overviews. These provide the relative and absolute benefits and harms of thyroid hormones in 
multilayered evidence summaries and decision aids available in MAGIC (https://app.magicapp.org/) to support 
shared decisions and adaptation of this guideline.
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Visual summary of recommendation
or
No thyroid
hormones
Thyroid hormones
Levothyroxine
StrongStrong WeakWeak
We recommend against thyroid hormone therapy for patients with subclinical hypothyroidism
Interventions compared
Recommendation
Population
Daily oral medication, normally tablets, 
often long-term treatment
Overdosage can lead to hyperthyroidism symptoms 
Should be taken 4 hours apart from any 
products containing calcium or iron
Long-term regular visits and blood samples 
to monitor hormone levels
Regular visits and blood samples 
to monitor progression or resolution
The panel expects little variability in how patients weigh 
the lack of benefit against the possible harms
Potential harms, and in particular risk of dying, may be 
valued differently by patients depending on their age, 
quality of life and comorbidities
Values and preferences
TSH levels may vary with stress, transient disease or with 
age. Elevated levels thus often revert to normal without 
treatment
There is no clear evidence on how to reliably attribute 
symptoms to subclinical hypothyroidism
TSH levels and symptoms
Key practical issues
No thyroid hormones Thyroid hormones
Adults with 
  subclinical   
  hypothyroidism
Does not apply to:
May not apply to:
Including:
Women who are or trying to become pregnant
Patients with no symptoms
(diagnosed after screening)
Patients with non-specific symptoms
Patients with severe symptoms
Patients with TSH above 20  mIU/L
Young adults (such as <30 years)
Elevated levels of thyroid 
stimulating hormone (TSH)
Normal free T4 
(thyroxine) levels
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Comparison of benefits and harms
For the elderly - about 65 years and older
No thyroid hormones Thyroid hormonesNo important difference
For younger people (such as 65 and younger)
No thyroid hormones Thyroid hormonesNo important difference
No important difference
3.6Depressive symptoms High
Evidence quality
Mean score: 0-21 (Low better)
Mean score: 0-infinity (High better)
Events per 1000 people
EQ-5D score: -0.59-1 (High better)
Mean score: 0-100 (Low better)
No important difference
No important difference
No important difference
No important difference
Cognitive function High27.1 28.1
General quality of life High0.85 0.83
Thyroid-related symptoms High16.7 16.5
Fatigue / tiredness High28.6 29.0
27Mortality* Low
After 1 year
After 2 years
After 1.5 years
3.3
14
10.9Side effects Moderate
Mean score: 0-100 (Low better)
No important difference10.3
No important difference
48Cardiovascular events* Low54 No important difference
No important difference
3.6Depressive symptoms High
Evidence quality
Mean score: 0-21 (Low better)
Mean score: 0-infinity (High better)
Events per 1000 people
EQ-5D score: -0.59-1 (High better)
Mean score: 0-100 (Low better)
No important difference
No important difference
No important difference
No important difference
Cognitive function Low27.1 29.7
General quality of life Moderate0.85 0.82
Thyroid-related symptoms High16.7 16.4
Fatigue / tiredness Moderate28.6 29.0
27Mortality Very low
After 1 year
After 2 years
After 1.5 years
3.3
14
10.9Side effects Low
Mean score: 0-100 (Low better)
No important difference10.3
No important difference
48Cardiovascular events Very low54 No important difference
Includes all the evidence, including from the largest TRUST trial 
conducted among an elderly population with comorbidities (see Figure 2)
The results of the systematic review were dominated by the large TRUST trial, conducted among the elderly. Therefore, the 
panel examined the evidence without this trial whenever possible. However, TRUST was the only study reporting on harms.
* Only a few deaths were observed, in a single trial. For mortality, we are 95% confident that the difference is between 
5 fewer to 62 more deaths per 1000 patients taking levothyroxine. For cardiovascular events, we are 95% confident 
that the difference is between 28 fewer to 62 more events per 1000 patients taking levothyroxine
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Subclinical hypothyroidism (SCH) is a biochemical 
state. The thyroid stimulating hormone (TSH) level 
is elevated, but the free T4 (thyroxine) level is nor-
mal. Some people may experience symptoms linked 
to the abnormality. Other data have suggested links 
to overt hypothyroidism and adverse outcomes such 
as increased risk of coronary heart disease. So it is 
reasonable to ask whether treatment with thyroid 
hormones might help symptoms, prevent overt hypo-
thyroidism, or avoid longer term heart problems. Box 
1 extends and references this understanding.
This guideline was triggered by a systematic review,15 
summarising all studies on this question. It includes a 
large and new trial specifically in older people with TSH.16 
The results of the review might change practice. The main 
infographic provides an overview of the relative and 
absolute benefits and harms of treating SCH with thyroid 
hormones in standard GRADE format. Box 2 shows all 
of the articles and evidence linked in this Rapid Recom-
mendation package.
Current practice
When to test for SCH
Historically, US guidelines recommended five-yearly 
screening of asymptomatic adults aged 35 years and 
older to identify thyroid dysfunction,17 but it is uncertain 
if such screening has any clinical benefits.18
In clinical practice, thyroid function can be checked 
as part of routine screening or for diagnostic purposes in 
those with possible hypothyroidism based on physical 
or mental health signs and symptoms. In the UK about 
25% of adults have thyroid function tests every year.19 A 
recent overview showed an increase in the use of thyroid 
function tests over time.20
Patients and clinicians (general practitioners, intern-
ists, and endocrinologists) are commonly faced with 
abnormal thyroid function tests consistent with SCH. All 
parties collaboratively need to decide if and how to act.
When to treat SCH
Guidelines generally recommend thyroid hormones for 
adults with TSH levels above 10 mIU/L. For those with 
lower TSH levels, most guidelines recommend treatment 
only when people are younger, symptomatic, or have other 
indications for prescribing (such as cardiovascular disease 
or antibodies to thyroid peroxidase). Table 1 summarises 
current guidance from various organisations.5-22
In many countries, the use of levothyroxine is increas-
ing,4 with a top ranking among the most prescribed drugs 
in the US in 2015.23 Increasing treatment of SCH with 
thyroid hormone, and of levothyroxine in particular, is 
the most likely explanation for this increase. Research 
showed that prevalence of treated SCH has doubled from 
1996 to 2006 and that people with TSH <10 mIU/L were 
prescribed levothyroxine 1.3 times more in 2009 than in 
2001 in the UK.19 This increased prevalence of treated 
SCH was confirmed in Norwegian population surveys, 
despite a stable prevalence of the condition itself.24 Other 
evidence includes a study by Taylor19 showing that a 
third of adults were offered treatment after a single TSH 
WHAT YOU NEED TO KNOW
•   Thyroid hormones should not be routinely 
offered to adults with SCH (strong 
recommendation according to GRADE).
•   Thyroid hormones do not lead to important 
benefits for adults with SCH for quality of 
life or thyroid related symptoms including 
depressive symptoms and fatigue
•   Taking a pill and attending periodic 
testing on an ongoing or lifelong basis is 
burdensome
•   This recommendation builds on a recent 
systematic review and meta-analysis, which 
included the results of a new randomised 
controlled trial
•   If implemented, this recommendation may 
substantially alter prescribing trends, which 
show that thyroid hormones are increasingly 
prescribed, most probably due to SCH
Box 1 | Overview of subclinical hypothyroidism (SCH)
What is SCH?
The definition of SCH varies. About 90% of all patients with 
SCH have TSH levels between 4 and 10 mIU/L.1 TSH levels 
may increase with age,2 and a slight increase of TSH may be 
normal for older people.
About 62% of TSH levels between 4 and 10 mIU/L 
normalise without intervention within five years.3 There is 
biological variation in TSH levels. Levels may rise in response 
to stress and transient disease.4 This biological variation in 
TSH values, means that one abnormal TSH level should be 
followed by a repeat blood test to confirm the diagnosis.5
According to the International Classification of Diseases 
(ICD), SCH does not have a separate code, but is typically 
labelled as “hypothyroidism, unspecified”.
How common is it?
It affects 4-20% of the adult population.6 This wide 
variation is due to poor consensus about the cut-off level 
for the diagnosis of SCH and regional variation between 
populations. It is more common in women, in older people, 
and those of white ethnicity.6
What are the symptoms?
Around 1 in 3 patients with SCH have no symptoms at all.7 
The type of symptoms people link to SCH include those 
of overt hypothyroidism: fatigue, muscle cramps, cold 
sensitivity, dry skin, voice changes, and constipation.8 
Other symptoms include poor memory, slowed thinking, 
weak muscles, puffy eyes, anxiety, and depression.7-10 Many 
of these symptoms are not specific to hypothyroidism. 
Around 20-25% of people with normal TSH levels report one 
or two of these symptoms.7 The relation between symptoms 
and biochemical TSH levels remains unclear.
What is the long term outlook?
The risk of progression to overt hypothyroidism ranges 
between 2% and 5% a year.11 Presence of antibodies to 
thyroid peroxidase and, in particular, higher TSH levels 
increase this risk.11-13
Observational data suggest that SCH is associated with 
an increased risk of coronary heart disease, heart failure, 
and cardiovascular mortality, particularly in those with TSH 
levels >10 mIU/L.1 14 Such associations were not found for 
most adults with TSH levels of 5-10 mIU/L.1 14
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65-93 years.16 Many participants had common comorbidi-
ties: 14% had ischaemic heart disease, 12% atrial fibril-
lation, 51% hypertension, 16% diabetes, and 12% had 
osteoporosis,16 representative of a general elderly popula-
tion. Because of its size, results of the TRUST trial dominate 
the results of the systematic review. For that reason, and 
to estimate the effect in younger patients, the guideline 
panel also looked at the results of the systematic review 
excluding the TRUST trial (see below).
The evidence applies to a broad range of adults with 
SCH as included in the systematic review. Some adults 
consulted physicians because of symptoms, others did 
not and were diagnosed after routine screening. The 
severity of symptoms, reported in seven studies (1263 
adults) was mild to moderate. No studies included only 
patients with severe symptoms. For younger people (that 
is, those <30 years of age) and for patients with unusually 
high TSH levels (>20 mIU/L with normal T4 levels) the 
evidence remains more indirect, although this concerns 
only a small minority of patients.
Understanding the recommendation
Who does it apply to?
The recommendation applies to most adults, with SCH 
after at least two consecutive thyroid function tests, with 
or without mild to moderate symptoms, who are consid-
ering initiating thyroid hormone treatment. Box 3 shows 
situations where the guideline does not or may not apply.
Absolute benefits and harms
The panel made a strong recommendation against thyroid 
hormones for SCH, because there were no important ben-
efits from treatment. In addition, we cannot rule out the 
possibility of harms.
testing. Not all of these adults may actually have SCH as 
TSH levels fluctuate and may revert to normal without 
treatment.
Finally, some patients with symptoms may receive a 
trial of levothyroxine to evaluate improvement of symp-
toms, but in such an approach it is difficult to separate real 
from placebo effects. Once levothyroxine is started, most 
adults stay on the drug for several years.19
The evidence
The systematic review that triggered this guideline com-
pared the effects of thyroid hormone treatment to that of 
no treatment or placebo in adults with SCH.15Figure 2 pre-
sents an overview of the characteristics of the randomised 
controlled trials (RCTs) and participants included in the 
review.
The systematic review includes 21 studies; the largest of 
which is the TRUST trial. This study examined the effects of 
thyroid hormone for SCH in over 700 elderly people aged 
Table 1 | Current guidance on thyroid hormone treatment for subclinical hypothyroidism
Organisation Recommendation
National Institute for Health 
and Care Excellence (NICE) CKS 
guidelines, 201821
• TSH >10 mIU/L: 
- Age <70 years, treat 
- Age ≥70 years, watch and wait
• TSH 4-10 mIU/L: 
- Age <65 years with symptoms, consider trial 
- Age ≥65 years, watch and wait
European Thyroid Association 
(ETA), 20135
• Age <70 years: 
- TSH >10 mIU/L, treat 
- TSH <10 mIU/L with symptoms, start trial 
- TSH <10 mIU/L without symptoms, observe
• Age >70 years: 
- TSH <10 mIU/L, observe 
- TSH >10 mIU/L, consider treatment if clear symptoms or high cardiovascular risk
American Thyroid Association 
(ATA), 20128
• TSH >10 mIU/L, consider treatment
• TSH <10 mIU/L, consider treatment if symptoms suggestive of hypothyroidism, 
positive antibodies to thyroid peroxidase, or evidence of atherosclerotic 
cardiovascular disease, heart failure, or risk factors for these diseases
UpToDate, 201822 • TSH <7 mIU/L: 
- Age >65/70 years, observe 
- Age <65/70 years, treat if symptoms, observe without symptoms
• TSH 7-10 mIU/L: 
- Age >65/70 years, treat if symptoms, observe without symptoms 
- Age <65 years, treat
• TSH >10 mIU/L: treat
Box 2 | Linked sources in this BMJ Rapid Recommendations 
cluster
• Bekkering GE, Agoritsas T, Lytvyn L, et al. Thyroid hormones 
for subclinical hypothyroidism: a clinical practice 
guideline. BMJ 2019;365:l2006
 – Summary of the results from the Rapid 
Recommendations process
• Feller M, Snel M, Moutzouri E, et al. Association of thyroid 
hormone therapy with quality of life and thyroid-related 
symptoms in patients with subclinical hypothyroidism: 
a systematic review and meta-analysis. JAMA 
2018;320:1349-59 doi:10.1001/jama.2018.13770
 – Review and meta-analysis of all available randomised 
trials that assessed thyroid hormones for subclinical 
hypothyroidism
• MAGICapp (https://app.magicapp.org/public/guideline/
nyqWPn)
 – Expanded version of the results with multilayered 
recommendations, evidence summaries, and decision 
aids for use on all devices
Box 3 | Exceptions to this BMJ Rapid Recommendation
This recommendation does not apply to
• Women who are trying to become pregnant. Such women 
were excluded from the studies. A systematic review of 
observational studies suggests that pregnant women with 
SCH may be at increased risk of adverse outcomes for both 
mother and baby.25 Guidelines recommend levothyroxine 
for pregnant women depending on TSH level and presence 
of antibodies to thyroid peroxidase26
• Those with very high TSH levels (>20 mIU/L) and with 
normal T4 (thyroxine) levels. These findings could suggest 
overt hypothyroidism but would affect only a few patients
This recommendation may not apply to
• Those with severe symptoms, as few were included in 
the studies reviewed. However, there is no clear evidence 
on how to attribute symptoms to SCH reliably, even with 
severe symptoms
• Very young adults (such as ≤30 years old). Few of these 
patients were included in the studies, probably because 
SCH is so uncommon at younger ages
• Women at risk of unplanned pregnancy. Clinicians may 
consider offering thyroid hormones because pregnant 
women with SCH may be at increased risk of adverse 
outcomes for mother and baby25
• Patients who already take thyroid hormones. The evidence 
presented here looked at the effect of starting medication 
and only indirectly informs stopping it
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On top of the absence of benefit, the panel were con-
cerned about a signal of harm in those treated. There were 
between five fewer and 62 more deaths per year in the 
treatment group (this is the 95% confidence interval). 
This interval includes the possibility of benefit (5 fewer 
deaths) as well as harm (62 more deaths). Additionally, 
these deaths were evaluated in only one trial with a two 
year follow-up.16 For these reasons, the panel had low cer-
For older people (≥65 years)
There was high certainty that there is little to no difference 
in general quality of life (QoL), thyroid related symptoms, 
depressive symptoms, fatigue, cognitive function, mus-
cle strength, and body mass index (BMI). The results are 
consistent across these outcomes, which strengthens our 
confidence that there really is a lack of benefit (see main 
infographic).
ALL EVIDENCE ALL EVIDENCE WITHOUT TRUST TRIAL
NUMBER OF TRIALS 21
NUMBER OF PATIENTS 2192 
DATA SOURCES
Use this information to gauge how
similar your patients’ conditions are
to those of people studied in the trials 
NUMBER OF TRIALS 20
NUMBER OF PATIENTS 1455 
TRIAL CHARACTERISTICS
PATIENT CHARACTERISTICS
0 400200 600 800
20
Min
737
Max
20
Min
369
Max
0 20 40 10060 80
0 5 1510
20 6040 80
0 400200 600 800
0 20 40 10060 80
0 5 1510
20 6040 80
NUMBER OF 
PATIENTS
Range
TRIAL
FUNDING
PATIENT
PARTNERSHIP
TESTING
METHODS
MEAN AGE, YEARS
at baseline
SEX
    % women
MEAN THYROID-
STIMULATING
HORMONE (THS)
 mIU/L at baseline
Not funded by industry 12
Funded by industry 1
Either did not declare or received
funding from mixed sources
8 *
*
*
POPULATION
AT BASELINE
TSH max 10 mIU/l 6
Mean TSH >10 2
Reported burden of symptoms
(mild to moderate)
7
51-100% with positive
TPO antibodies
7
Not funded by industry 11
Funded by industry 1
Either did not declare or received
funding from mixed sources
8
Trials that involved patients 
in design or conduct
0 Trials that involved patients 
in design or conduct
0
Trials where TSH was tested 
at least twice
15 Trials where TSH was tested 
at least twice
14

Min

Max

Min

Max

Min

Max

Mean

Min

Max

Mean
.
Min
.
Max
.
Mean
.
Min
.
Max
.
Mean
+1 as a
subgroup

*
*
* TSH max 10 mIU/l 6
Mean TSH >10 2
Reported burden of symptoms 
(mild to moderate)
6
51-100% with positive
TPO antibodies
7

*
*
*
*
*
*
*
*
*
*
* Not possible to determine from information publushed in the systematic review
Fig 2 |  Characteristics of participants and trials included in the systematic review of the effects of thyroid hormone treatment for 
subclinical hypothyroidism (SCH)
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probably no evidence of any benefits, and possibly little 
or no difference in risk for harms. For some outcomes, 
uncertainty increased: for example, for fatigue, certainty 
was rated down to moderate due to indirectness (the 
evidence only comes from older adults). There is low cer-
tainty about the lack of effect on cognitive function, but 
the panel recognises that this outcome is less relevant to 
younger, healthier patients.
The same is true for harms. However, the panel was 
concerned about the burden of lifelong treatment and 
the limited evidence about possible long term harms of 
thyroid hormones (such as adverse cardiovascular effects). 
In addition, patients may experience a delay in diagnosis 
of another condition (such as mood disorder).
tainty in this estimate. None the less, the panel agreed that 
the possibility of harms contributes towards the strong 
recommendation.
For younger people (such as <65)
There was no important benefit shown in younger groups. 
However, the panel’s certainty in the estimates was 
slightly lower. There is moderate to high certainty that 
such patients experience little or no benefit from thyroid 
hormone therapy for SCH.
The panel re-analysed the data without TRUST (the 
largest trial, performed exclusively in older people). The 
panel examined the age distribution of each study’s par-
ticipants. The results in younger people remain consistent: 
PRACTICAL ISSUES
Treatment with levothyroxine
MEDICATION
ROUTINE
No treatment
COSTS &
ACCESS
TEST & VISIT
Regular visits and blood samples to 
monitor progression or resolution
Anxiety of taking no treatment for a 
known condition
Costs accumulate with regular testing
Daily oral medication, normally tablets, often 
long term treatment
Long term regular visits and blood samples 
to monitor hormone levels
Overdosage can lead to hyperthyroidism 
symptoms (decrease in bone mineral density, 
atrial fibrillation and other symptoms of drug 
induced hyperthyroidism)
Levothyroxine should be taken 4 hours apart 
from any supplements that contain calcium 
or iron
Anxiety of taking treatment long term for a 
known condition
Costs accumulate with long term treatment 
and regular testing
Should be taken on empty stomach or 3-4 
hours since last meal. Do not eat for 30-60 
minutes after taking levothyroxine
ADVERSE EFFECTS,
INTERACTIONS &
ANTIDOTE
EMOTIONAL
WELL-BEING
FOOD & DRINKS
Patients may be anxious about the occurrence of overt clinical hypothyroidism
Fig 3 |  Practical issues about the use or non-use of thyroid hormones for subclinical hypothyroidism (SCH)
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Updates to this article
Table 2 shows the evidence that has emerged since the 
publication of this article. As new evidence is published, 
a group will assess this new evidence and make a judg-
ment on the extent that it is expected to alter the recom-
mendation.
At the time of publication, we identified one new trial 
in trial registries:
•   IEMO, assessing the effect of thyroid hormones versus 
placebo in elderly aged 80 years with SCH, 80-plus 
thyroid trial (NTR3851 in Netherlands Trial Register).
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Values and preferences
The panel expects little variability in how patients per-
ceive the lack of benefit. Harms may be more important 
as SCH is not a fatal disease, and most people are reason-
ably well when they are diagnosed. In addition, potential 
harms, and in particular risk of dying, may be valued dif-
ferently by patients depending on their quality of life and 
comorbidities.
Practical issues
Figure 3 outlines the key practical issues about the use or 
non-use of thyroid hormones. The option to treat is more 
burdensome for patients as treatment requires daily and 
possibly long term medication, follow-up, and blood tests. 
Both treating and not treating may result in anxiety.
Cost and resources
Although we did not take costs and resources into account 
beyond direct costs to patients (such as out-of-pocket 
costs), thyroid hormones cannot be cost effective given 
the lack of important benefit, potential for harm, and 
associated costs.
Uncertainty
Future research could explore whether there is an unidenti-
fied subgroup of patients who do benefit from treatment. 
No evidence of a potential subgroup or even a trend was 
observed in the current body of evidence, consistently 
across outcomes. Such research could consider whether 
there is more benefit in groups of people for whom there is 
less direct evidence and therefore more uncertainty, such as
•   Younger people (about ≤30 years old)
•   People with more severe symptoms.
There is uncertainty about potential harms, as these 
were studied only in the TRUST trial, which found only a 
few events after a follow-up of only two years. However, 
this uncertainty becomes important only when there is 
evidence of benefit.
HOW WAS THIS RECOMMENDATION CREATED?
Our international panel included methodologists, general 
practitioners, internists, endocrinologists, and patient 
partners with subclinical hypothyroidism (SCH) (see 
appendix 1 on bmj.com for details of panel members). 
They decided on the scope of the recommendation and 
identified patient-important outcomes to inform the 
recommendations.
The panel met online to discuss the evidence and 
formulate a recommendation. No member had a financial 
conflict of interest; intellectual and professional conflicts 
were minimised and are transparently described (appendix 
2 on bmj.com). The panel followed the BMJ Rapid 
Recommendations procedures for creating a trustworthy 
recommendation,27 including using the GRADE approach to 
critically appraise the evidence and create recommendations 
(appendix 3 on bmj.com).28 The panel considered the 
benefits, harms, and burdens and other practical issues 
related to thyroid hormones in the context of SCH, as well 
as expected variations in patient values and preferences.29 
Within the GRADE approach, recommendations can be 
either strong or weak (also known as conditional), and for or 
against a specific course of action.30
Table 2 | New evidence which has emerged after initial 
publication
Date
New 
evidence Citation Findings
Implications for 
recommendation(s)
There are currently no updates to the article.
HOW PATIENTS WERE INVOLVED IN THE CREATION OF THIS 
ARTICLE
Two people with lived experience of subclinical 
hypothyroidism were members of the panel and participated 
in the whole process. They identified and rated outcomes, 
and helped lead the discussion on values and preferences 
in a videoconference and in email discussions with the 
full panel. They noted patients may feel anxious about 
deteriorating or developing overt hypothyroidism when no 
treatment was given. To address this, regular follow-up is 
very important. They also mentioned that it is difficult for 
patients to make a decision when feeling unwell. We thank 
them for their contribution.
 o
n
 20 M
ay 2019 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.l2006 on 14 May 2019. Downloaded from 
No commercial reuse: See rights and reprints http://www.bmj.com/permissions 9 of 9
R A P I D  R E C O M M E N DAT I O N S
28 Guyatt GH, Oxman AD, Vist GE, et al. GRADE Working Group. GRADE: 
an emerging consensus on rating quality of evidence and strength of 
recommendations. BMJ 2008;336:924-6. 10.1136/bmj.39489.470347.
AD.  pmid:18436948.
29 Andrews JC, Schünemann HJ, Oxman AD, et al. GRADE guidelines: 
15. Going from evidence to recommendation-determinants of a 
recommendation’s direction and strength. J Clin Epidemiol 2013;66:726-
35. 10.1016/j.jclinepi.2013.02.003.  pmid:23570745.
30 Guyatt GH, Oxman AD, Kunz R, et al. GRADE Working Group. Going from 
evidence to recommendations. BMJ 2008;336:1049-51. 10.1136/
bmj.39493.646875.AE.  pmid:18467413.
Published by the BMJ Publishing Group Limited. For permission to use 
(where not already granted under a licence) please go to http://group.
bmj.com/group/rights-licensing/permissions 
8 Garber JR, Cobin RH, Gharib H, et al. American Association of Clinical 
Endocrinologists and American Thyroid Association Taskforce on 
Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism 
in adults: cosponsored by the American Association of Clinical 
Endocrinologists and the American Thyroid Association. Endocr Pract 
2012;18:988-1028. 10.4158/EP12280.GL.  pmid:23246686.
9 Almeida C, Brasil MA, Costa AJ, et al. Subclinical hypothyroidism: 
psychiatric disorders and symptoms. Braz J Psychiatry 2007;29:157-9. 
10.1590/S1516-44462007000200013  pmid:17639255.
10 Hong JW, Noh JH, Kim DJ. Association between subclinical thyroid 
dysfunction and depressive symptoms in the Korean adult population: 
The 2014 Korea National Health and Nutrition Examination 
Survey. PLoS One 2018;13:e0202258. 10.1371/journal.
pone.0202258.  pmid:30106989.
11 Vanderpump MPJ, Tunbridge WMG, French JM, et al. The incidence of 
thyroid disorders in the community: a twenty-year follow-up of the 
Whickham Survey. Clin Endocrinol (Oxf) 1995;43:55-68. 10.1111/
j.1365-2265.1995.tb01894.x.  pmid:7641412.
12 Huber G, Staub JJ, Meier C, et al. Prospective study of the spontaneous 
course of subclinical hypothyroidism: prognostic value of thyrotropin, 
thyroid reserve, and thyroid antibodies. J Clin Endocrinol Metab 
2002;87:3221-6. 10.1210/jcem.87.7.8678.  pmid:12107228.
13 Díez JJ, Iglesias P. Spontaneous subclinical hypothyroidism in patients 
older than 55 years: an analysis of natural course and risk factors 
for the development of overt thyroid failure. J Clin Endocrinol Metab 
2004;89:4890-7. 10.1210/jc.2003-032061.  pmid:15472181.
14 Gencer B, Collet TH, Virgini V, et al. Thyroid Studies Collaboration. 
Subclinical thyroid dysfunction and the risk of heart failure 
events: an individual participant data analysis from 6 
prospective cohorts. Circulation 2012;126:1040-9. 10.1161/
CIRCULATIONAHA.112.096024.  pmid:22821943.
15 Feller M, Snel M, Moutzouri E, et al. Association of thyroid hormone 
therapy with quality of life and thyroid-related symptoms in patients with 
subclinical hypothyroidism: a systematic review and meta-analysis. JAMA 
2018;320:1349-59. 10.1001/jama.2018.13770.  pmid:30285179.
16 Stott DJ, Rodondi N, Kearney PM, et al. TRUST Study Group. Thyroid 
hormone therapy for older adults with subclinical hypothyroidism. N Engl J 
Med 2017;376:2534-44. 10.1056/NEJMoa1603825.  pmid:28402245.
17 Ladenson PW, Singer PA, Ain KB, et al. American Thyroid Association 
guidelines for detection of thyroid dysfunction. Arch Intern Med 
2000;160:1573-5. 10.1001/archinte.160.11.1573  pmid:10847249.
18 Rugge JB, Bougatsos C, Chou R. Screening and treatment of thyroid 
dysfunction: an evidence review for the U.S. Preventive Services 
Task Force. Ann Intern Med 2015;162:35-45. 10.7326/M14-
1456.  pmid:25347444.
19 Taylor PN, Iqbal A, Minassian C, et al. Falling threshold for 
treatment of borderline elevated thyrotropin levels-balancing 
benefits and risks: evidence from a large community-
based study. JAMA Intern Med 2014;174:32-9. 10.1001/
jamainternmed.2013.11312.  pmid:24100714.
20 O’Sullivan JW, Stevens S, Hobbs FDR, et al. Temporal trends in use of tests 
in UK primary care, 2000-15: retrospective analysis of 250 million tests. 
BMJ 2018;363:k4666. 10.1136/bmj.k4666  pmid:30487169.
21 National Institute for Health and Care Excellence. Clinical Knowlegde 
Summaries. Subclinical hypothyroidism (non-pregnant). 2018. https://cks.
nice.org.uk/hypothyroidism#!scenario:1.
22 Ross DS. Subclinical hypothyroidism in nonpregnant adults. UpToDate. 
2018. https://www.uptodate.com/contents/subclinical-hypothyroidism-
in-nonpregnant-adults.
23 WebMD. The 10 Most-Prescribed and Top-Selling Medications. 2015. 
https://www.webmd.com/drug-medication/news/20150508/most-
prescribed-top-selling-drugs.
24 Asvold BO, Vatten LJ, Bjøro T. Changes in the prevalence of hypothyroidism: 
the HUNT Study in Norway. Eur J Endocrinol 2013;169:613-20. 10.1530/
EJE-13-0459.  pmid:23975540.
25 Maraka S, Ospina NM, O’Keeffe DT, et al. Subclinical hypothyroidism in 
pregnancy: a systematic review and meta-analysis. Thyroid 2016;26:580-
90. 10.1089/thy.2015.0418.  pmid:26837268.
26 Alexander EK, Pearce EN, Brent GA, et al. 2017 Guidelines of the American 
Thyroid Association for the Diagnosis and Management of Thyroid 
Disease During Pregnancy and the Postpartum. Thyroid 2017;27:315-89. 
10.1089/thy.2016.0457.  pmid:28056690.
27 Siemieniuk RA, Agoritsas T, Macdonald H, Guyatt GH, Brandt L, Vandvik PO. 
Introduction to BMJ Rapid Recommendations. BMJ 2016;354:i5191. 
10.1136/bmj.i5191.  pmid:27680768.
1Academic Centre for General Practice, Department of Public Health and 
Primary Care, KU Leuven, Belgium
2Belgian Centre for Evidence-Based Medicine, Cochrane Belgium
3Division of General Internal Medicine and Division of Clinical Epidemiology, 
University
Hospitals of Geneva, Geneva, Switzerland
4Department of Health Research Methods, Evidence and Impact, McMaster 
University, Hamilton, Canada
5Department of Medicine, Innlandet Hospital Trust-division, Gjøvik, Norway
6Institute of Primary Health Care (BIHAM), University of Bern, Bern, 
Switzerland
7Department of General Internal Medicine, Inselspital, Bern University 
Hospital, University of Bern, Bern, Switzerland
8Munich, Germany
9Milan, Italy
10Knowledge and Evaluation Research Unit in Endocrinology (KER_Endo), 
Division of Endocrinology, Diabetes, Metabolism and Nutrition, Department 
of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
11Division General Internal Medicine, University Hospitals of Geneva, 1205 
Geneva, Switzerland
12Department of Medicine, Division of Endocrinology, University of Florida, 
Gainesville, Florida, USA
13Primary Care Clinical Unit, Faculty of Medicine, University of Queensland, 
Brisbane Qld 4029, Australia
14HRB Centre for Primary Care Research and Department of General Practice, 
Royal College of Surgeons in Ireland (RCSI), Dublin, Ireland
15Department of Endocrinology/General Internal Medicine, Leiden 
University Medical Center, Leiden, Netherlands
16Effective Basic Services (eBASE), Bamenda, Cameroon
17Department of Health Research Methods, Evidence and Impact, McMaster 
University, Hamilton, Ontario, Canada
18Institute of Health and Society, Faculty of Medicine, University of Oslo, 
Oslo, Norway
19Department of Medicine, Innlandet Hospital Trust-division, Gjøvik, Norway
20Norwegian Institute of Public Health, Oslo, Norway
21Dutch College of General Practitioners, Utrecht, Netherlands
 o
n
 20 M
ay 2019 by guest. Protected by copyright.
http://www.bmj.com/
BM
J: first published as 10.1136/bmj.l2006 on 14 May 2019. Downloaded from 
